Sarepta Therapeutics, Inc.
SRPT
$16.66
$0.261.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.58% | 47.15% | 64.89% | 59.15% | 52.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.58% | 47.15% | 64.89% | 59.15% | 52.97% |
| Cost of Revenue | 110.18% | 91.05% | 102.53% | 78.73% | 9.33% |
| Gross Profit | -121.00% | -27.16% | 1.14% | 10.95% | 261.01% |
| SG&A Expenses | -11.86% | 0.30% | 8.72% | 13.32% | 15.77% |
| Depreciation & Amortization | 9.02% | -0.82% | 2.79% | 21.34% | 54.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.61% | 60.31% | 69.22% | 56.90% | 11.43% |
| Operating Income | -401.62% | -206.15% | -102.45% | -23.60% | 181.43% |
| Income Before Tax | -369.28% | -294.89% | -138.78% | -582.07% | 150.14% |
| Income Tax Expenses | -56.20% | 155.76% | 126.63% | 390.57% | 60.81% |
| Earnings from Continuing Operations | -403.27% | -322.84% | -222.54% | -1,570.01% | 143.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -403.27% | -322.84% | -222.54% | -1,570.01% | 143.89% |
| EBIT | -401.62% | -206.15% | -102.45% | -23.60% | 181.43% |
| EBITDA | -339.73% | -130.32% | -48.36% | -47.66% | 214.49% |
| EPS Basic | -388.23% | -311.23% | -221.51% | -1,881.02% | 140.26% |
| Normalized Basic EPS | -371.73% | -178.00% | -78.80% | -9.12% | 183.46% |
| EPS Diluted | -401.84% | -333.22% | -271.25% | -2,550.76% | 139.04% |
| Normalized Diluted EPS | -404.56% | -212.04% | -135.38% | -26.79% | 175.25% |
| Average Basic Shares Outstanding | 5.29% | 3.78% | 4.29% | 5.04% | 5.80% |
| Average Diluted Shares Outstanding | 0.45% | 4.26% | 7.45% | 8.44% | 12.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |